Peripheral Artery Disease Therapeutics Market

Report Overview

The global peripheral artery disease therapeutics market was pegged at US$ 2.2 billion in 2021 and is expected to witness a CAGR of 5.5% during the forecast period.

Market Fundamental 

In peripheral artery disease, also known as peripheral arterial disease, blood flow to the arms or legs is decreased due to clogged or restricted arteries. The legs or arms — typically the legs — do not get adequate blood flow to meet demand in peripheral artery disease (PAD). Symptoms such as claudication, as well as others, may result from this. Typically, peripheral artery disease indicates an accumulation of fatty deposits in the arteries (atherosclerosis). Vascular narrowing brought on by atherosclerosis can lessen blood flow to the arms and legs. Treatment for peripheral artery disease involves physical activity, a good diet, and abstinence from nicotine and smoking. Additionally, numerous patients with peripheral artery disease exhibit minimal or no symptoms. Some people get leg pain whenever you walk (claudication).

Muscle aches or cramps in the arms or legs that start during exertion and stop with rest are indications of claudication. The leg is where the pain is most frequently felt. From little to severe pain is experienced.

[4564643]

Market Dynamics 

The use of interventional devices such as drug-eluting agents, atherectomy devices, and others has expanded as a result of the changing healthcare infrastructure, which is fueling market expansion. With the aid of a catheter, plaque can be removed from arteries during atherectomy, which is becoming popular for treating peripheral arterial disorders (PADs). Additionally, the demand for minimally invasive or non-invasive endovascular procedures has grown recently due to their quicker recovery times and lower risk of problems following surgery. This will help the market even more. In addition, the population's unhealthy lifestyle and increased use of alcohol, cigarettes, and smoking will increase the amount of cardiac arrests, blood clots, and other heart disorders in the years to come, increasing the need for PAD therapy. Furthermore, the prevalence of peripheral artery disorders is projected to increase in the future due to the rise in the global geriatric population. While the number of individuals aged 60 and older is expected to quadruple by 2050, people aged 80 or older are expected to triple between 2020 and 2050, according to WHO research published in October 2021. Ageing and the development of diseases like diabetes, high blood pressure, and heart issues, among others, are clearly associated.

Market Ecosystem 

The global peripheral artery disease therapeutics market has been analysed from two perspectives including therapeutics class and region. 

Peripheral Artery Disease Therapeutics Market by Therapeutics Class

[234234]

Based on therapeutics class, the globalperipheral artery disease therapeutics market has been segmented into antithrombotic drugs (antiplatelet drugs and anticoagulant drugs), antihypertensive drugs, lipid-lowering drugs and others. The antithrombotic drugs (antiplatelet drugs and anticoagulant drugs) segment dominated the market during forecast period. The risk of heart attack and stroke may be decreased by using an antiplatelet drug like aspirin or clopidogrel. Patient can use these medications to treat illnesses like diabetes, high cholesterol, and high blood pressure (statin meds and antihypertensive medications). By treating the PAD risk factors, these medications also lower your risk of heart attack and stroke.

Peripheral Artery Disease Therapeutics Market by Region

Based on region, the global peripheral artery disease therapeutics market has been segmented into North America, Europe, Asia Pacific and Rest of the world. North America currently controls the peripheral arterial disease (PAD) industry Due to the expanding use of cutting-edge technology. Peripheral arterial disease (PAD) market growth in the region will also be aided by the occurrence of different innovative medication molecules to improve the treatment process throughout the course of the projected year.

Due to an increase in the patient pool, Asia-Pacific is predicted to have significant growth in the peripheral arterial disease (PAD) market. The peripheral arterial disease (PAD) market is expected to increase in the region over the next several years as a result of the expanding investment in the healthcare industry.

Competitive Landscape 

Some of the prominent market player in the global peripheral artery disease therapeutics market include 

• Bayer AG
• Bristol-Myers Squibb
• AstraZeneca
• DAIICHI Sankyo Company, Limited
• Merck & Co Inc.
• Novo Nordisk A/S
• Emcure Pharmaceuticals
• Novartis AG
• Johnson & Johnson Services, Inc.
• Symic Bio, Inc.

 The peripheral artery disease industry is extremely competitive due to lucrative growth potential. In the recent years, businesses have adopted a variety of development techniques. For instance, in September 2020, the LIFE-BTK clinical trial was begun by Abbott Laboratories to evaluate the efficacy and security of its Esprit BTK Everolimus-Eluting Resorbable Scaffold System. People with advanced peripheral artery disease are likely to benefit from this Investigational Device Exemption (IDE) trial being conducted in the United States (PAD).

Strategic Development 

• In August 2021, FDA approval of XARELTO (Rivaroxaban) Plus Aspirin for the treatment of patients with Lower-Extremity Revascularization (LER) as a result of symptomatic PAD was announced by Janssen Pharmaceutical Companies of Johnson & Johnson.
• In June 2020, Becton, Dickinson and Company acquired Straub Medical AG, a private company. For the treatment of venous and peripheral arterial disorders, Straub Medical AG develops medical atherectomy and thrombectomy devices (PAD). This acquisition has improved the ability of Becton, Dickinson and Company to treat peripheral artery disease.
• In January 2020, a large pharmaceutical and life sciences company, Bayer, and SidekickHealth, a Nordic digital therapeutics company, have partnered strategically to provide a platform for medication management and lifestyle change
• In December 2018, Aralez Pharma, a top pharmaceutical business that makes medications used in the treatment of PAD such ZONTIVITY, has been acquired by Nuvo Pharma (Vorapaxar). 

Frequently Asked Questions About This Report